Brokerages Set AxoGen, Inc. (NASDAQ:AXGN) PT at $13.80

Shares of AxoGen, Inc. (NASDAQ:AXGN) have been assigned a consensus recommendation of “Buy” from the five ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $13.80.

Several equities research analysts recently weighed in on AXGN shares. Canaccord Genuity Group reissued a “buy” rating and set a $15.00 price target on shares of AxoGen in a research report on Thursday, June 20th. JMP Securities lifted their target price on AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a report on Friday, August 9th. Raymond James assumed coverage on AxoGen in a report on Monday, July 1st. They set an “outperform” rating and a $13.00 price target on the stock. Finally, StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a research report on Friday, August 9th.

AxoGen Price Performance

Shares of NASDAQ:AXGN opened at $13.02 on Tuesday. The business has a fifty day moving average price of $10.11 and a 200-day moving average price of $8.37. The company has a debt-to-equity ratio of 0.70, a current ratio of 3.51 and a quick ratio of 2.32. The company has a market capitalization of $569.04 million, a PE ratio of -26.04 and a beta of 1.12. AxoGen has a 1-year low of $3.45 and a 1-year high of $13.35.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10. The company had revenue of $47.91 million for the quarter, compared to the consensus estimate of $43.27 million. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. As a group, equities analysts expect that AxoGen will post -0.33 EPS for the current fiscal year.

Institutional Trading of AxoGen

Several large investors have recently modified their holdings of the company. Koss Olinger Consulting LLC purchased a new stake in AxoGen during the second quarter valued at $75,000. Lazard Asset Management LLC grew its stake in shares of AxoGen by 30.1% during the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 2,671 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of AxoGen during the 2nd quarter valued at about $125,000. BNP Paribas Financial Markets increased its position in shares of AxoGen by 8.6% during the 1st quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after purchasing an additional 1,651 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of AxoGen by 8.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider’s stock worth $240,000 after purchasing an additional 2,204 shares during the period. Institutional investors own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.